THERAPIX BIOSCIENCES LTD Inactive Instrument
Therapix Biosciences Ltd Share Price TEL AVIV STOCK EXCHANGE
Equities
TRPX
IL0010951403
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - ILS | - |
|
| 05:00pm | SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio | MT |
| 03/06 | SciSparc Ltd. Secures Strategic Advantage with Grant of European Patent | CI |
| Sales 2022 | 1.35 4.96 112.38 | Sales 2023 | 2.88 10.6 240.2 | Capitalization | 2.56M 9.41M 213M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -7.36M -167M | Net income 2023 | -5M -18.41M -417M | EV / Sales 2022 | 11,45,812 x |
| Net cash position 2022 | 3.55M 13.06M 296M | Net cash position 2023 | 5M 18.41M 417M | EV / Sales 2023 | -8,48,893 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-0.34
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
More press releases
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +23.58% | 45.07B | |
| +30.84% | 23.39B | |
| +25.28% | 16.08B | |
| +19.32% | 14.6B | |
| +67.99% | 14.01B | |
| -0.05% | 6.79B | |
| -13.00% | 6.38B | |
| -8.87% | 5.73B | |
| +13.53% | 5.64B |
- Stock Market
- Equities
- SPRC Stock
- TRPX Stock
